JNJ Diabetes Data Benefit Lilly, Hurt Merck - Barron's


Barron's

JNJ Diabetes Data Benefit Lilly, Hurt Merck
Barron's
Our conversations with experts at the American Diabetes Association (ADA) suggest many feel this may in fact be a class effect, potentially related to volume depletion in patients who have a history of peripheral artery disease or prior amputation. The ...
Diabetes Drug Invokana Makes Promising ProgressCBS St. Louis
New drug shows promise for treating heart disease in diabetes patientsPharmacy Today, American Pharmacists Association, pharmacist.com
Diabetes drug helps hearts tooIndependent Online
Science Times -The Statesman
all 14 news articles »